Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philip A Beer

Showing results (1-10 of 59) with videos related to

Pageof 6
Sort By:
Current Opinion in Hematology|August 10, 2011
The pathogenesis of essential thrombocythemiaPhilip A Beer
Trends in Cancer|July 26, 2017
Modeling Normal and Disordered Human HematopoiesisPhilip A Beer, Connie J Eaves
Hematology. American Society of Hematology. Education Program|December 17, 2009
Pathogenesis and management of essential thrombocythemiaPhilip A Beer, Anthony R Green
Cell Stem Cell|June 19, 2012
Hematopoietic stem cell heterogeneity takes center stageMichael R Copley, Philip A Beer, Connie J Eaves
Haematologica|June 11, 2010
Comparison of different criteria for the diagnosis of primary myelofibrosis reveals limited clinical utility for measurement of serum lactate dehydrogenasePhilip A Beer, Peter J Campbell, Anthony R Green
Genomics|November 4, 2020
Defining the clinical genomic landscape for real-world precision oncologyPhilip A Beer, Susanna L Cooke, David K Chang, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 31, 2019
Reasons to be testing: the dawn of complex molecular profiling in routine oncology practicePhilip A Beer, Susanna L Cooke, David K Chang, et al.
Blood|November 26, 2010
How I treat essential thrombocythemiaPhilip A Beer, Wendy N Erber, Peter J Campbell, et al.
Blood|August 14, 2010
Independently acquired biallelic JAK2 mutations are present in a minority of patients with essential thrombocythemiaPhilip A Beer, Christina A Ortmann, Peter J Campbell, et al.
British Journal of Haematology|October 4, 2007
Prevalance of JAK2 V617F and exon 12 mutations in polycythaemia veraLinda M Scott, Philip A Beer, Anthony J Bench, et al.
Pageof 6

Showing results (1-10 of 59) with videos related to

Sort By:
Pageof 6
Current Opinion in Hematology|August 10, 2011
The pathogenesis of essential thrombocythemiaPhilip A Beer
Trends in Cancer|July 26, 2017
Modeling Normal and Disordered Human HematopoiesisPhilip A Beer, Connie J Eaves
Hematology. American Society of Hematology. Education Program|December 17, 2009
Pathogenesis and management of essential thrombocythemiaPhilip A Beer, Anthony R Green
Cell Stem Cell|June 19, 2012
Hematopoietic stem cell heterogeneity takes center stageMichael R Copley, Philip A Beer, Connie J Eaves
Haematologica|June 11, 2010
Comparison of different criteria for the diagnosis of primary myelofibrosis reveals limited clinical utility for measurement of serum lactate dehydrogenasePhilip A Beer, Peter J Campbell, Anthony R Green
Genomics|November 4, 2020
Defining the clinical genomic landscape for real-world precision oncologyPhilip A Beer, Susanna L Cooke, David K Chang, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 31, 2019
Reasons to be testing: the dawn of complex molecular profiling in routine oncology practicePhilip A Beer, Susanna L Cooke, David K Chang, et al.
Blood|November 26, 2010
How I treat essential thrombocythemiaPhilip A Beer, Wendy N Erber, Peter J Campbell, et al.
Blood|August 14, 2010
Independently acquired biallelic JAK2 mutations are present in a minority of patients with essential thrombocythemiaPhilip A Beer, Christina A Ortmann, Peter J Campbell, et al.
British Journal of Haematology|October 4, 2007
Prevalance of JAK2 V617F and exon 12 mutations in polycythaemia veraLinda M Scott, Philip A Beer, Anthony J Bench, et al.
Pageof 6